Study of intraventricular cerliponase alfa for CLN2 disease
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Enzyme Replacement Therapy
Intraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls. Serious adverse events included failure of the intraventricular device and device-related infections. (Funded by BioMarin Pharmaceutical and others; CLN2 ClinicalTrials.gov numbers, NCT01907087 and NCT02485899 .).